RECRUITING

Ethanol Induces Skeletal Muscle Autophagy

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

In this study we plan to demonstrate that ethanol induces skeletal muscle autophagy to degrade MAA adducts.

Official Title

Mechanisms of Skeletal Muscle Proteolysis With Ethanol Consumption: an Integrated Molecular Metabolic Approach

Quick Facts

Study Start:2015-05-18

Study Completion:2025-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03209791

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* clinical, biochemical, imaging criteria and liver biopsy where available * Age 18 - 65 years old * Serum liver transaminases (i.e. ALT and AST) 40 IU/L * Normal liver ultrasound * Age 18 - 65 years old	* Poorly controlled diabetes mellitus (HbA1C\>9.5 g/dl) * Untreated Hyper- / hypo- thyroidism * Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL * Active intravenous drug use * History of bowel surgery or gastric bypass surgery * Medications known to alter muscle protein metabolism (i.e. corticosteroids, tamoxifen, high-dose estrogen, testosterone or anabolic steroids) * Metastatic disease, Advanced cardiac or pulmonary disease * Pregnancy * Coagulopathy- INR \>1.4 and platelet count \<80,000/ml.

Inclusion Criteria

Exclusion Criteria

* clinical, biochemical, imaging criteria and liver biopsy where available
* Age 18 - 65 years old
* Serum liver transaminases (i.e. ALT and AST) 40 IU/L
* Normal liver ultrasound
* Age 18 - 65 years old

* Poorly controlled diabetes mellitus (HbA1C\>9.5 g/dl)
* Untreated Hyper- / hypo- thyroidism
* Patients on dialysis, renal disease with serum creatinine 1.5 mg/dL
* Active intravenous drug use
* History of bowel surgery or gastric bypass surgery
* Medications known to alter muscle protein metabolism (i.e. corticosteroids, tamoxifen, high-dose estrogen, testosterone or anabolic steroids)
* Metastatic disease, Advanced cardiac or pulmonary disease
* Pregnancy
* Coagulopathy- INR \>1.4 and platelet count \<80,000/ml.

Contacts and Locations

Study Contact

Revathi Penumatsa, MPH

CONTACT

2164450688

penumar@ccf.org

Annette Bellar, MSLA

CONTACT

2166365247

bellara@ccf.org

Principal Investigator

Srinivasan Dasarathy, MD

PRINCIPAL_INVESTIGATOR

The Cleveland Clinic

Study Locations (Sites)

Cleveland Clinic

Cleveland, Ohio, 44195

United States

Collaborators and Investigators

Sponsor: The Cleveland Clinic

Srinivasan Dasarathy, MD, PRINCIPAL_INVESTIGATOR, The Cleveland Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2015-05-18

Study Completion Date2025-12-31

Study Record Updates

Study Start Date2015-05-18

Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

Alcoholic Liver Disease